John R. Stuelpnagel, Director at 10x Genomics, Inc. (TXG), sold 9,300 shares at $143.44 ($1.3M) on 2021-05-17, disclosed to the SEC on 2021-05-19.
Open-market sale of $1.3M TXG by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $139.59 | 500 | $70K | 5.3% |
| 2 | $140.34 | 2,600 | $365K | 27.7% |
| 3 | $141.36 | 1,800 | $254K | 19.3% |
| 4 | $141.36 | 1,800 | $254K | 19.3% |
| 5 | $142.48 | 1,000 | $142K | 10.8% |
| 6 | $143.44 | 1,000 |
| $143K |
| 10.9% |
| 7 | $144.49 | 600 | $87K | 6.6% |
| Total | $141.53 avg | 9,300 | $1.3M | 100% |
| Filing → |
| TXG | SELL | 2023-06-07 | $549K | — | Filing → |
| TXG | SELL | 2022-01-04 | $1.5M | — | Filing → |
| TXG | SELL | 2021-12-03 | $756K | — | Filing → |